Kymera Therapeutics

OverviewSuggest Edit

Kymera Therapeutics is a biotechnology company aimed to create medicines for patients with previously untreatable diseases. The company specializes in the field of targeted protein degradation (TPD) accessing the body’s innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins. Its proprietary integrated degradation platform, Pegasus, consists of informatics-driven target identification, novel E3 ligases, proprietary ternary complex predictive modeling capabilities and degradation tools.

TypePrivate
Founded2017
HQWatertown, MA, US
Websitekymeratx.com

Latest Updates

Employees (est.) (Apr 2021)86(+11%)
Job Openings30
Cybersecurity ratingAMore

Key People/Management at Kymera Therapeutics

Nello Mainolfi

Nello Mainolfi

Founder, President, Chief Executive Officer & Director
Jared Gollob

Jared Gollob

Chief Medical Officer
Bruce Jacobs

Bruce Jacobs

Chief Financial Officer
Richard Chesworth

Richard Chesworth

Chief Scientific Officer
Brian Albarran

Brian Albarran

Vice President, Strategy and Operations
Paige Cochran

Paige Cochran

Vice President, Human Resources
Show more

Kymera Therapeutics Office Locations

Kymera Therapeutics has an office in Watertown
Watertown, MA, US (HQ)
200 Arsenal Yards Blvd #230
Show all (1)

Kymera Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2017

Kymera Therapeutics total Funding

$197 m

Kymera Therapeutics latest funding size

$102 m

Time since last funding

a year ago

Kymera Therapeutics investors

Kymera Therapeutics's latest funding round in March 2020 was reported to be $102 m. In total, Kymera Therapeutics has raised $197 m
Show all financial metrics

Kymera Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Kymera Therapeutics Online and Social Media Presence

Embed Graph

Kymera Therapeutics News and Updates

Kymera Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides a Business Update

Initiated Phase 1 first-in-human dosing of KT-474, a first-in-class oral IRAK4 degrader to treat immune-inflammatory diseases

Kymera Therapeutics Announces First-in-Human Dose in Phase 1 Trial of KT-474, a First-in-Class IRAK4 Protein Degrader to Treat Immune-Inflammatory Diseases

KT-474 is the first IRAK4 degrader, and first heterobifunctional small molecule protein degrader outside of oncology, to enter clinical development

Kymera Therapeutics to Present at Upcoming March Investor Conferences

WATERTOWN, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in upcoming investor confer…

Kymera Therapeutics to Present at Upcoming February Investor Conferences

WATERTOWN, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at two upcoming investor confer…

Kymera Therapeutics Strengthens Leadership with Key Appointments and Promotions

WATERTOWN, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointments of Ashwin Gollerkeri, MD, as Senior Vice Pre…

Kymera Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021

WATERTOWN, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at the virtual 39th Annual J.P.…
Show more

Kymera Therapeutics Blogs

American Association of Cancer Research (AACR) 2021 Annual Meeting, April 10-15, 2021

Poster Presentation: Mechanisms Underlying Synergistic Activity of KT-413, a Targeted Degrader of IRAK4 and IMiD Substrates in Hematopoietic Cancers The post American Association of Cancer Research (AACR) 2021 Annual Meeting, April 10-15, 2021 appeared first on Kymera Therapeutics.

Oxford Global’s Virtual Symposium: Targeted Protein Degradation & PROTAC, February 16-17, 2021

Poster Presentation: Discovery of Potent and Selective STAT3 Targeted Protein Degraders with Excellent in vitro and in vivo ADME Properties The post Oxford Global’s Virtual Symposium: Targeted Protein Degradation & PROTAC, February 16-17, 2021 appeared first on Kymera Therapeutics.

2nd Annual North American Protein Degradation Congress, February 16-24, 2021

Poster Presentation: Targeted Protein Degradation in Oncology and Beyond The post 2nd Annual North American Protein Degradation Congress, February 16-24, 2021 appeared first on Kymera Therapeutics.

62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition, December 5-8, 2020

Poster Presentation: Targeting MYD88-Mutant DLBCL with IRAKIMiDs: A Comparison to IRAK4 Kinase Inhibition and Evaluation of Synergy with Rational Combinations The post 62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition, December 5-8, 2020 appeared first on Kymera Therape…

Becoming CEO: The First 18 Months

I’ve held many titles and even more roles at Kymera since founding the company with Bruce Booth and Atlas Venture four years ago. But it’s been just over 12 months since we announced my appointment to CEO, and nearly 18 months in the role. Looking back now, I could not imagine a more challenging and…

IRAK4 Degrader to Take on Innate Immunity, November 3, 2020

Mullard, A. IRAK4 degrader to take on innate immunity. Nat Biotechnol 38, 1221–1223 (2020). https://doi.org/10.1038/s41587-020-0724-8 The post IRAK4 Degrader to Take on Innate Immunity, November 3, 2020 appeared first on Kymera Therapeutics.
Show more

Kymera Therapeutics Frequently Asked Questions

  • When was Kymera Therapeutics founded?

    Kymera Therapeutics was founded in 2017.

  • Who are Kymera Therapeutics key executives?

    Kymera Therapeutics's key executives are Nello Mainolfi, Jared Gollob and Bruce Jacobs.

  • How many employees does Kymera Therapeutics have?

    Kymera Therapeutics has 86 employees.

  • Who are Kymera Therapeutics competitors?

    Competitors of Kymera Therapeutics include Foghorn Therapeutics, Urovant Sciences and Praxis Precision Medicines.

  • Where is Kymera Therapeutics headquarters?

    Kymera Therapeutics headquarters is located at 200 Arsenal Yards Blvd #230, Watertown.

  • Where are Kymera Therapeutics offices?

    Kymera Therapeutics has an office in Watertown.

  • How many offices does Kymera Therapeutics have?

    Kymera Therapeutics has 1 office.